Quantcast

Latest H5N1 clinical trials Stories

2010-04-29 07:00:00

ROCKVILLE, Md., April 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) reported today that its trivalent seasonal influenza virus-like-particle (VLP)-based vaccine candidate was safe and immunogenic against the 2009-2010 seasonal influenza virus strains in older adults 60 years or higher in age. In a double-blind, active-controlled Phase II study of 480 randomized subjects, the safety, tolerability and immunogenicity of a single 15 microgram dose or 60 microgram dose (per...

2010-04-28 10:00:00

BETHESDA, Md., April 28 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc., a private biopharmaceutical company focused on the development of innovative vaccine products, announced today that results from two Phase I studies of its norovirus virus-like particle (VLP) vaccine candidate were presented today at the 13th Annual Conference on Vaccine Research. Sponsored by the National Foundation of Infectious Diseases, the conference is being held in Bethesda, Maryland, from April 26-28, 2010....

2010-04-22 07:00:00

ROCKVILLE, Md., April 22 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), has determined the Company's proposal to provide recombinant influenza vaccine products and manufacturing capabilities for pandemic preparedness is in the competitive range for award of an advanced development contract. Novavax submitted its proposal in September 2009 in...

3d1aeba0c50d50768e0f6f5af55cbd431
2010-03-25 12:30:00

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) have discovered structural similarities between the H1N1 "swine flu" virus that caused an outbreak last year 2009 and the virus responsible for the pandemic of 1918, according to a March 24 press release from the National Institutes of Health. The relationship between the two strains could help make future vaccines more effective. "This study defines an unexpected similarity between two pandemic-causing strains...

2010-03-08 07:00:00

ROCKVILLE, Md., March 8 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that the enrollment of over 3,500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus-like-particle (VLP) pandemic influenza vaccine study. With the 1,000 subjects already enrolled in Stage A of the trial, the enrollment in this pivotal trial is now complete with over 4,500 subjects. In this Stage B of Novavax's pivotal study of H1N1 influenza vaccine candidate, a...

2010-03-04 08:00:00

SAN FRANCISCO, March 4 /PRNewswire/ -- Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has closed a $12.5 million Series B financing, led by Care Capital of Princeton NJ. The funding will be used to advance the Company's lead product, an oral vaccine for Avian influenza, through Phase I clinical trials. "We are excited to be within a year of launching Phase I clinical trials of our potentially revolutionary platform technology, and delighted to be...

2010-02-19 05:00:00

ROCKVILLE, Md., Feb. 19 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today presented to the world's leading pandemic influenza vaccine experts a summary of the recent preliminary safety and immunogenicity data from its Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study in Mexico. The presentation of the results were made by Maria Allende, M.D., at the invitation-only 6th World Health Organization (WHO) Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical...

2010-02-18 07:00:00

ROCKVILLE, Md., Feb. 18 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that Fast Company has placed Novavax as one of the Top Ten Most Innovative Companies in the Biotech industry. In its selection, Fast Company's editorial team analyzed information on thousands of businesses across the globe. They noted that it was not just about revenue growth and profit margins that Fast Company endeavored to identify, it was also about creative models and progressive cultures...

2010-02-16 07:00:00

ROCKVILLE, Md., Feb. 16 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) The Board of Directors of Novavax, Inc., announced today the election of Stanley Erck as Executive Chairman. The effective date of this leadership change is immediately. Previously, Mr. Erck served as President and Chief Executive Officer of Iomai Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a...

2010-02-08 11:41:00

ROCKVILLE, Md., Feb. 8 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax's trivalent seasonal influenza Virus-like Particle (VLP) vaccine. The vaccine matched the influenza strains recommended for the 2008-2009 influenza season including H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/2007, and B/Florida/04/2006 strains. The study enrolled 241 subjects,...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related